Status:

ACTIVE_NOT_RECRUITING

Resiliency Training in Adolescents With NF1 and NF2

Lead Sponsor:

Massachusetts General Hospital

Collaborating Sponsors:

United States Department of Defense

Conditions:

Neurofibromatoses

Eligibility:

All Genders

12-17 years

Phase:

NA

Brief Summary

This randomized controlled trial for resiliency training in adolescents with Neurofibromatosis 1 and Neurofibromatosis 2 via secure live video to determine the efficacy two stress and symptom manageme...

Detailed Description

Neurofibromatosis (NFs) are rare genetic conditions with cure. Adolescents with NF experience more symptoms of depression and anxiety, higher levels of stress associated with coping with NF symptoms, ...

Eligibility Criteria

Inclusion

  • Has a diagnosis of NF1 or NF2 and is between the ages of 12-17
  • Is capable of completing and fully understanding the informed consent process/assent and the study procedures and assessments in English; has parental approval for participation
  • English speaking and at least a 3rd grade self-reported and parent reported reading level
  • Self reported/parent reported difficulties coping with stress and NF symptoms

Exclusion

  • Has major medical co-morbidity not NF related expected to worsen in the next 12 months
  • Recent (within past 3 months) change in antidepressant medication
  • Recent participation in cognitive behavioral therapy or relaxation therapy (within past 3 months)
  • Has significant mental health diagnosis requiring immediate treatment (e.g., untreated bipolar disorder, psychotic disorder, active substance dependence)
  • Unable or unwilling to complete assessments electronically via REDCap
  • Unable or unwilling to participate in group videoconferencing sessions
  • Unable or unwilling to participate along with at least 1 parent in a video screening session

Key Trial Info

Start Date :

December 15 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 20 2026

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT03873610

Start Date

December 15 2019

End Date

February 20 2026

Last Update

December 26 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02140